Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2077
Gene Symbol: ERF
ERF
0.010 AlteredExpression phenotype BEFREE The level of vertigo immediately after injection was lower when the dexamethasone was injected at body temperature rather that at room temperature for both the VAS and CRS-4 (p < 0.05). 31130271 2020
Entrez Id: 3479
Gene Symbol: IGF1
IGF1
0.010 AlteredExpression phenotype BEFREE S-Ca (HR 1.21 (1.02; 1.44) p = 0.028) also predicted future fractures, whereas PTH, IGF-1, 25(OH) vitamin D, hormone replacement therapy, smoking, degree of physical activity, impaired vision and dizziness did not. 31720709 2020
Entrez Id: 1523
Gene Symbol: CUX1
CUX1
0.010 Biomarker phenotype BEFREE Patients were assessed with objective outcome measures (sensorial organization test and limits of stability-LOS-of CDP, modified timed up and go test-TUG-and number of falls) and with subjective outcome measures (dizziness handicap inventory and Short falls efficacy scale-international-Short FES-I) during a 12-month follow-up period. 30977081 2020
Entrez Id: 4878
Gene Symbol: NPPA
NPPA
0.010 Biomarker phenotype BEFREE Patients were assessed with objective outcome measures (sensorial organization test and limits of stability-LOS-of CDP, modified timed up and go test-TUG-and number of falls) and with subjective outcome measures (dizziness handicap inventory and Short falls efficacy scale-international-Short FES-I) during a 12-month follow-up period. 30977081 2020
Entrez Id: 111
Gene Symbol: ADCY5
ADCY5
0.010 Biomarker phenotype BEFREE Sixty-eight patients with AC/V-P shunts had a higher incidence of head trauma (P = 0.014), younger age at onset (P < 0.001), and lower incidence of dizziness (P = 0.013) than did those without AC/V-P shunts. 30797913 2019
Entrez Id: 551
Gene Symbol: AVP
AVP
0.010 Biomarker phenotype BEFREE We evaluated whether copeptin and S100b protein (PS100b) assessment, alone or in combination, could rule out stroke in patients visiting EDs for dizziness. 31387626 2019
Entrez Id: 1834
Gene Symbol: DSPP
DSPP
0.010 GeneticVariation phenotype BEFREE Of the incretin-based therapies, DPP-4Is had a lower risk of dizziness than GLP-1 RAs (OR: 0.76, 95% CI: 0.67 to 0.87; high quality). 31788342 2019
Entrez Id: 8864
Gene Symbol: PER2
PER2
0.010 Biomarker phenotype BEFREE This was an interventional study using medical records to collect data for acute dizziness presentations before (period 1, 2012-2014) and after (period 2, 2016-2017) the implementation of a management algorithm. 31098875 2019
Entrez Id: 3769
Gene Symbol: KCNJ13
KCNJ13
0.010 Biomarker phenotype BEFREE Finally, we propose that SVD-mediated dysregulation of cerebral blood pressure is linked to dizziness during standing and walking in elderly patients with "unexplained" dizziness. 31239134 2019
Entrez Id: 4311
Gene Symbol: MME
MME
0.010 GeneticVariation phenotype BEFREE The incidence of hypotension (OR 1.44; 95% CI 1.15-1.80; P < 0.05) and dizziness (OR 1.46; 95% CI 1.32-1.62; P < 0.05) was obviously increased in neprilysin-RAS inhibition compared with RAS inhibition. 31153654 2019
Entrez Id: 2671
Gene Symbol: GFER
GFER
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 7170
Gene Symbol: TPM3
TPM3
0.010 Biomarker phenotype BEFREE While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic. 31738426 2019
Entrez Id: 2242
Gene Symbol: FES
FES
0.010 Biomarker phenotype BEFREE A sample of 662 79-year-olds (404 women, 258 men) were investigated with questions regarding dizziness, previous falls and falls efficacy [estimated according to the falls efficacy scale Swedish version (FES (S))]. 31489596 2019
Entrez Id: 2740
Gene Symbol: GLP1R
GLP1R
0.010 Biomarker phenotype BEFREE Ranking probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, respectively). 31788342 2019
Entrez Id: 83932
Gene Symbol: SPRTN
SPRTN
0.010 Biomarker phenotype BEFREE Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials. 31152441 2019
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.010 Biomarker phenotype BEFREE Ranking probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, respectively). 31788342 2019
Entrez Id: 260431
Gene Symbol: COPD
COPD
0.010 Biomarker phenotype BEFREE Accordingly, DB is often underdiagnosed or misdiagnosed, given the similarity of its associated symptoms (dyspnea, tachycardia, and dizziness) to those of other common cardiopulmonary diseases such as COPD and asthma. 30758427 2019
Entrez Id: 842
Gene Symbol: CASP9
CASP9
0.010 GeneticVariation phenotype BEFREE CASP9 genotype confers gentamicin susceptibility in intratympanic treatment of intractable vertigo caused by Ménière's disease. 30907242 2019
Entrez Id: 2670
Gene Symbol: GFAP
GFAP
0.010 Biomarker phenotype BEFREE Dizziness was associated with reaction time decrements, GFAP or NfL suppression, as well as Aβ peptide elevation. 31408492 2019
Entrez Id: 1803
Gene Symbol: DPP4
DPP4
0.010 Biomarker phenotype BEFREE As a new class of antidiabetic drug, incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have raised concerns about symptoms of withdrawal in patients with type 2 diabetes mellitus (T2DM), such as dizziness and headache. 31788342 2019
Entrez Id: 80025
Gene Symbol: PANK2
PANK2
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 4914
Gene Symbol: NTRK1
NTRK1
0.010 Biomarker phenotype BEFREE While TRK inhibitors have a favourable overall safety profile, select on-target adverse events, including weight gain, dizziness/ataxia and paraesthesias, are occasionally observed and should be monitored in the clinic. 31738426 2019
Entrez Id: 6448
Gene Symbol: SGSH
SGSH
0.010 AlteredExpression phenotype BEFREE For HSS, the active group showed reduced hangover symptoms while there were higher levels of nausea, headache, anorexia, tremulousness, diarrhoea and dizziness in the placebo group (p < 0.05) at hour 10 post-intoxication. 30922154 2019
Entrez Id: 9311
Gene Symbol: ASIC3
ASIC3
0.010 GeneticVariation phenotype BEFREE However, whether the genetic variants of <i>ASIC3</i> are associated with people who suffer dizziness and balance impairment after mTBI remained unknown. 30804886 2019
Entrez Id: 100125288
Gene Symbol: ZGLP1
ZGLP1
0.010 Biomarker phenotype BEFREE Ranking probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, respectively). 31788342 2019